KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.

Anaïs Glatard, Sofia Friberg-Hietala, Lina Keutzer, Anna Hansson, Markus Johnsson, Fredrik Tiberg

Clin Pharmacokinet 64(7) 1079-1092

PMID40418492
PMCIDPMC12185581
DOI10.1007/s40262-025-01522-3
发表日期2025-05-26
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。
摘要

摘要

INTRODUCTION: Octreotide is a first-generation somatostatin receptor ligand (SRL) approved for acromegaly treatment. CAM2029 is a sustained-release subcutaneous octreotide injection designed to improve treatment convenience for patients and bioavailability over alternative SRL treatments. The aim of this analysis was to characterise the pharmacokinetic (PK) properties of CAM2029. METHODS: Using nonlinear mixed-effects modelling, 4098 observations from three trials, including 216 healthy participants and participants with acromegaly, were used to develop a population PK model of octreotide after administration of CAM2029 or immediate-release (IR) octreotide. Simulated octreotide plasma concentration profiles after administration of clinically justified dosing regimens of CAM2029 and octreotide IR were compared. RESULTS: Octreotide disposition was best described by a two-compartmental distribution with a first-order elimination model. The rapid initial and slow subsequent drug release of CAM2029 was best characterised by two simultaneous first-order absorption processes, whereas octreotide IR absorption was described by a single first-order pathway. The model was qualified to describe octreotide concentrations and supported the robustness of dosing CAM2029 every 4 weeks (Q4W) ± 1 week. Simulations indicated that the average concentration during a dosing interval at steady state for 20 mg CAM2029 Q4W was similar to 0.25 mg octreotide IR every 8 h, but with reduced daily fluctuation. CONCLUSIONS: This population PK model supports the use of CAM2029 as a potential alternative treatment option to both octreotide IR and long-acting repeatable (LAR) for acromegaly treatment. The octreotide bioavailability for CAM2029 was similar to octreotide IR and approximately 5 to 6 fold higher than octreotide LAR, with a more rapid onset. TRIAL REGISTRATIONS: 2020-002643-35 (EudraCT), NCT04076462 (date of registration: 3rd September 2019), NCT04125836 (date of registration: 14th October 2019).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Schematic of the population pharmacokinetic model. CL clearance, f fast fraction of the dose associated with fast first-order absorption, IR immediate release, MAT mean absorption time, MAT fast mean absorption time associated with fast first-order absorption, MAT Octreotide IR , mean absorption time of octreotide IR, MAT slow mean absorption time associated with slow first-order absorption, Q inter-compartmental clearance, V volume of distribution
非 KM Figure
Fig. 2Fig. 2 Forest plots illustrating the effects of covariates on octreotide PK a C max,ss and b AUC τ,ss conditioned on a typical reference individual (75 kg and injection site as the abdomen), based on the final octreotide PK model. These values were calculated based on 250 sampled parameter vectors from the variance-covariance matrix computed from a non-parametric bootstrap with 30 samples. Closed dots and error bars (where present), together with their specific values, represent the median of the predicted relative change from the reference individual and its associated 90% CIs. There is no CI of the median since the WT effects on the parameters were fixed. The typical reference individual had the injection site as the abdomen or injection site as missing. AUC τ,ss area under the concentration-time curve during a dosing interval at steady state, CI confidence interval, C max,ss maximum concentration during a dosing interval at steady state, PK pharmacokinetic
非 KM Figure
Fig. 3Fig. 3 Prediction-corrected visual predictive checks of octreotide PK plasma concentrations versus time after last dose using the final octreotide PK model. Data shown for a patients with acromegaly following CAM2029 administration, b healthy participants following CAM2029 administration, and c healthy participants following octreotide IR administration. Data are presented on a semi-logarithmic scale. Time points associated with observations below the limit of quantification were included in the VPC. CI confidence interval, IR immediate-release, PK pharmacokinetic, VPC visual predictive check
非 KM Figure
Fig. 4Fig. 4 Arithmetic means of simulated octreotide concentrations are shown a following the first dose of 20 mg CAM2029 ( n = 200) and b at steady state for 20 mg CAM2029 Q4W ( n = 200), alongside arithmetic means of simulated octreotide concentrations following 0.25 mg octreotide IR Q8H ( n = 200) and 20 mg octreotide LAR (data on file). IR immediate-release, LAR long-acting repeatable, PopPK population pharmacokinetic, Q4W every 4 weeks, Q8H every 8 h
非 KM Figure